230 related articles for article (PubMed ID: 12081629)
1. Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: III. Retinoids.
Citver AS; Shields AM; Ciaccia LM; Schulingkamp RJ; Raffa RB
J Clin Pharm Ther; 2002 Jun; 27(3):161-8. PubMed ID: 12081629
[TBL] [Abstract][Full Text] [Related]
2. Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: II. Glutamate (Ant)agonists.
Carfagno ML; Hoskins LA; Pinto ME; Yeh JC; Raffa RB
Ann Pharmacother; 2000 Jun; 34(6):788-97. PubMed ID: 10860140
[TBL] [Abstract][Full Text] [Related]
3. Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists.
Dixon DA; Fenix LA; Kim DM; Raffa RB
Ann Pharmacother; 1999 Apr; 33(4):480-8. PubMed ID: 10332540
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia.
Reynolds GP
Acta Psychiatr Scand Suppl; 1994; 380():36-40. PubMed ID: 7914046
[TBL] [Abstract][Full Text] [Related]
5. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
6. The importance of dopamine D4 receptors in the action and development of antipsychotic agents.
Reynolds GP
Drugs; 1996 Jan; 51(1):7-11. PubMed ID: 8741229
[TBL] [Abstract][Full Text] [Related]
7. Dopamine receptors and schizophrenia.
Reynolds GP
Biochem Soc Trans; 1996 Feb; 24(1):202-5. PubMed ID: 8674664
[No Abstract] [Full Text] [Related]
8. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
[TBL] [Abstract][Full Text] [Related]
9. Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action.
Sanyal S; Van Tol HH
J Psychiatr Res; 1997; 31(2):219-32. PubMed ID: 9278187
[TBL] [Abstract][Full Text] [Related]
10. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
[TBL] [Abstract][Full Text] [Related]
11. Targeting the dopamine D2 receptor in schizophrenia.
Seeman P
Expert Opin Ther Targets; 2006 Aug; 10(4):515-31. PubMed ID: 16848689
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D4 receptors: a new opportunity for research on schizophrenia.
Liégeois J; Eyrolles L; Bruhwyler J; Delarge J
Curr Med Chem; 1998 Apr; 5(2):77-100. PubMed ID: 9481035
[TBL] [Abstract][Full Text] [Related]
13. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action.
Wilson JM; Sanyal S; Van Tol HH
Eur J Pharmacol; 1998 Jun; 351(3):273-86. PubMed ID: 9721018
[TBL] [Abstract][Full Text] [Related]
14. Extrastriatal dopamine D
Nørbak-Emig H; Pinborg LH; Raghava JM; Svarer C; Baaré WFC; Allerup P; Friberg L; Rostrup E; Glenthøj B; Ebdrup BH
World J Biol Psychiatry; 2017 Oct; 18(7):539-549. PubMed ID: 27782768
[TBL] [Abstract][Full Text] [Related]
15. [The dopamin D3 receptor--the gray eminence of pharmacotherapy?].
Sumegi A; Varga E
Neuropsychopharmacol Hung; 2010 Sep; 12(3):405-11. PubMed ID: 20962360
[TBL] [Abstract][Full Text] [Related]
16. Do loxapine plus cyproheptadine make an atypical antipsychotic? PET analysis of their dopamine D2 and serotonin2 receptor occupancy.
Kapur S; Zipursky RB
Arch Gen Psychiatry; 1998 Jul; 55(7):666-8. PubMed ID: 9672060
[No Abstract] [Full Text] [Related]
17. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study.
Gurevich EV; Bordelon Y; Shapiro RM; Arnold SE; Gur RE; Joyce JN
Arch Gen Psychiatry; 1997 Mar; 54(3):225-32. PubMed ID: 9075463
[TBL] [Abstract][Full Text] [Related]
18. Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability.
Amato D; Vernon AC; Papaleo F
Neurosci Biobehav Rev; 2018 Feb; 85():146-159. PubMed ID: 28970021
[TBL] [Abstract][Full Text] [Related]
19. Deletion of dopamine D
Tomasella E; Bechelli L; Ogando MB; Mininni C; Di Guilmi MN; De Fino F; Zanutto S; Elgoyhen AB; Marin-Burgin A; Gelman DM
Proc Natl Acad Sci U S A; 2018 Mar; 115(13):3476-3481. PubMed ID: 29531031
[TBL] [Abstract][Full Text] [Related]
20. Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment.
Urigüen L; García-Fuster MJ; Callado LF; Morentin B; La Harpe R; Casadó V; Lluis C; Franco R; García-Sevilla JA; Meana JJ
Psychopharmacology (Berl); 2009 Oct; 206(2):313-24. PubMed ID: 19652957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
